A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens

In the house dust mite (HDM) Dermatophagoides pteronyssinus, Der p 1, 2, 5, 7, 21, and 23 have been identified as the most important allergens. The aim of this study was to define hypoallergenic peptides derived from the sequences of the six allergens and to use the peptides and the complete allergens to study antibody, T cell, and cytokine responses in sensitized and nonsensitized subjects.

[1]  R. Valenta,et al.  Underestimation of house dust mite-specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs. , 2018, The Journal of allergy and clinical immunology.

[2]  R. Pawankar,et al.  Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? , 2018, The journal of allergy and clinical immunology. In practice.

[3]  M. Rattray,et al.  Evolution of IgE responses to multiple allergen components throughout childhood , 2018, The Journal of allergy and clinical immunology.

[4]  A. Chevigné,et al.  Emerging roles of the protease allergen Der p 1 in house dust mite-induced airway inflammation. , 2018, The Journal of allergy and clinical immunology.

[5]  W. Thomas.  IgE and T‐cell responses to house dust mite allergen components , 2018, Molecular immunology.

[6]  R. Valenta,et al.  Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches , 2018, Current Allergy and Asthma Reports.

[7]  P. Panzner,et al.  Cross-sectional study on sensitization to mite and cockroach allergen components in allergy patients in the Central European region , 2018, Clinical and Translational Allergy.

[8]  R. Valenta,et al.  Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice , 2018, EBioMedicine.

[9]  R. Gerth van Wijk,et al.  Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32 , 2018, The Journal of allergy and clinical immunology.

[10]  S. Durham,et al.  Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. , 2017, The Journal of allergy and clinical immunology.

[11]  A. Kaider,et al.  Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients , 2017, Scientific Reports.

[12]  R. Valenta,et al.  Recombinant allergy vaccines based on allergen-derived B cell epitopes , 2017, Immunology letters.

[13]  F. Chew,et al.  International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem , 2017, The World Allergy Organization journal.

[14]  L. Caraballo.  Mite allergens , 2017, Expert review of clinical immunology.

[15]  R. Valenta,et al.  Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance. , 2017, Seminars in immunology.

[16]  D. Postma,et al.  Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes , 2017, The Journal of allergy and clinical immunology.

[17]  T. Keil,et al.  Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life , 2017, The Journal of allergy and clinical immunology.

[18]  Norbert Meyer,et al.  Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. , 2016, The Journal of allergy and clinical immunology.

[19]  R. Valenta,et al.  Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy , 2016, EBioMedicine.

[20]  J. Davies,et al.  EAACI Molecular Allergology User's Guide , 2016, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[21]  R. Valenta,et al.  Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future , 2016, The Journal of allergy and clinical immunology.

[22]  J. Rolland,et al.  T Cell Epitope Peptide Therapy for Allergic Diseases , 2016, Current Allergy and Asthma Reports.

[23]  Bjoern Peters,et al.  Definition of a pool of epitopes that recapitulates the T cell reactivity against major house dust mite allergens , 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  R. Valenta,et al.  Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children , 2015, The Journal of allergy and clinical immunology.

[25]  R. Valenta,et al.  Poor association of allergen‐specific antibody, T‐ and B‐cell responses revealed with recombinant allergens and a CFSE dilution‐based assay , 2015, Allergy.

[26]  J. Bousquet,et al.  Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. , 2014, Methods.

[27]  Youngshin Han,et al.  The Indoor Level of House Dust Mite Allergen Is Associated with Severity of Atopic Dermatitis in Children , 2013, Journal of Korean medical science.

[28]  E. Unanue,et al.  Unconventional recognition of peptides by T cells and the implications for autoimmunity , 2012, Nature Reviews Immunology.

[29]  H. Grönlund,et al.  Variability of IgE reactivity profiles among European mite allergic patients , 2008, European journal of clinical investigation.

[30]  W. Thomas,et al.  IgE and IgG anti-house dust mite specificities in allergic disease. , 2006, The Journal of allergy and clinical immunology.

[31]  Peter D Sly,et al.  Downregulation of IgE antibody and allergic responses in the lung by epidermal biolistic microparticle delivery. , 2006, The Journal of allergy and clinical immunology.

[32]  B. Bohle,et al.  Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1 *01. , 2005, The Journal of allergy and clinical immunology.

[33]  J. Goldblatt,et al.  An immunoepidemiological approach to asthma: identification of in-vitro T cell response patterns associated with different wheezing phenotypes in children , 2005, The Lancet.

[34]  W. Thomas,et al.  Genetic variation of Der p 2 allergens: effects on T cell responses and immunoglobulin E binding , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[35]  R. Valenta,et al.  Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. , 2002, The Journal of allergy and clinical immunology.

[36]  Thomas,et al.  Cytokine responses to Der p 1 and Der p 7: house dust mite allergens with different IgE‐binding activities , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  G. Marks,et al.  House dust mite exposure as a risk factor for asthma: benefits of avoidance , 1998, Allergy.

[38]  D. Strachan,et al.  International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. , 1995, The European respiratory journal.

[39]  D. Marsh,et al.  Immunogenetic aspects of IgE-mediated responses. , 1994, Advances in experimental medicine and biology.

[40]  J. Lamb,et al.  Overlapping T-cell epitopes in the group I allergen of Dermatophagoides species restricted by HLA-DP and HLA-DR class II molecules. , 1994, The Journal of allergy and clinical immunology.

[41]  W. Thomas,et al.  An immunogenetic analysis of T-cell reactive regions on the major allergen from the house dust mite, Der p I, with recombinant truncated fragments. , 1994, The Journal of allergy and clinical immunology.

[42]  D. Wraith,et al.  Immunotherapy of autoimmune disease with synthetic peptides. , 1994, Immunology today (Amsterdam. Regular ed.).

[43]  H. Jansen,et al.  T cell epitopes of house dust mite major allergen Der p II. , 1993, Journal of immunology.

[44]  J. Bos,et al.  Serum-IgE-facilitated allergen presentation in atopic disease. , 1993, Journal of immunology.

[45]  J. D. de Vries,et al.  T cell activation-inducing epitopes of the house dust mite allergen Der p I. Proliferation and lymphokine production patterns by Der p I-specific CD4+ T cell clones. , 1992, Journal of immunology.

[46]  R. Valenta,et al.  Molecular Aspects of Allergens and Allergy. , 2018, Advances in immunology.

[47]  T. Hoffmann,et al.  Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.

[48]  L. Caraballo,et al.  Mites and allergy. , 2014, Chemical immunology and allergy.

[49]  M. Larché,et al.  Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. , 2013, The Journal of allergy and clinical immunology.

[50]  M. Larché.  T cell epitope-based allergy vaccines. , 2011, Current topics in microbiology and immunology.

[51]  M. Worm,et al.  Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. , 2011, The Journal of allergy and clinical immunology.

[52]  W. Thomas,et al.  Expression of Dermatophagoides pteronyssinus allergen, Der p II, in Escherichia coli and the binding studies with human IgE. , 1990, International archives of allergy and applied immunology.